A Phase 1 interventional study of Brivaracetam and Ethanol in Healthy Volunteers, sponsored by UCB Pharma SA. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-11.
Sponsored by UCB Pharma SA (part of UCB S.A.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate if Brivaracetam (BRV) influences the psychomotor and cognitive impairing effects of Ethanol
UCB Pharma SA is the lead sponsor of 28 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A: Ethanol + Brivaracetam
Drug: Brivaracetam · Other: Ethanol
Treatment B: Ethanol Placebo + Brivaracetam
Drug: Brivaracetam · Other: Ethanol Placebo
Treatment C: Ethanol + Brivaracetam Placebo
Other: Ethanol · Other: Brivaracetam Placebo
Strength: 200 mg (4 x 50 mg) Form: oral tablet Frequency: single dose Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1.
Form: intravenous infusion Frequency: continuous infusion Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L.
In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
Saccadic Eye Movements from 60 minutes Pre-Dose up to 10 hours Post-Dose
Average values of Latency (reaction time), Saccadic Peak Velocity, and Inaccuracy (difference between stimulus angle and corresponding saccade in percentages) will be calculated for all artifact-free saccades.
Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
Smooth pursuit eye movements from 60 minutes Pre-Dose up to 10 hours Post-Dose
The time during which the eyes are in smooth pursuit of the target will be calculated for each frequency and expressed as a percentage of stimulus duration. The average percentage of smooth pursuit for all stimulus frequencies will be used as a parameter.
Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
Adaptive tracking from 60 minutes Pre-Dose up to 10 hours Post-Dose
Performance will be scored after a fixed period of 3.5 minutes and reflected visuo motor control and vigilance. The average performance scores will be used in the analysis.
Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
Body sway from 60 minutes Pre-Dose up to 10 hours Post-Dose
The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. (antero-posterior sway in mm / 2 minutes)
Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
Visual Analog Scales for Mood From 60 minutes Pre-Dose up to 10 hours Post-Dose
Visual Analog Scales according to Bond and Lader
Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
Visual Analog Scale for alcohol intoxication From 60 minutes Pre-Dose up to 10 hours Post-Dose
The scale consists of a 10 cm line anchored on the left end by "sober" and on the right end by "drunk." Subjects mark a point on the line that best represents their subjective state corresponding to the condition tested. The result is a distance calculated from the mark on the line.
Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
Visual Verbal Learning Test from 1.5 hours Post-Dose up to 6 hours Post-Dose
Immediate recall, immediate recognition, delayed recall, and delayed recognition to evaluate memory
Time frame: From 1.5 hours Post-Dose up to 6 hours Post-Dose
Visual Analog Scales for Alertness From 60 minutes Pre-Dose up to 10 hours Post-Dose
Visual Analog Scales according to Bond and Lader
Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
Visual Analog Scales for Calmness From 60 minutes Pre-Dose up to 10 hours Post-Dose
Visual Analog Scales according to Bond and Lader
Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
The area under the plasma concentration-time curve from zero to infinity (AUC)
Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.
Time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose
The area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification [AUC(0-t)]
Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.
Time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose
The maximum plasma concentration (Cmax)
Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.
Time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose
The time to reach the maximum plasma concentration (tmax)
Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.
Time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose
The terminal disposition rate constant (λz) with the respective terminal half-life (t1/2)
Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.
Time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose
Serum Ethanol concentrations
Blood samples for Ethanol concentrations will be taken - 30 minutes, - 15 and - 5 minutes Pre-Dose, then 15, 30 and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, and 10 hours Post-Dose.
Time frame: From - 30 minutes Pre-Dose to 10 hours Post-Dose
Breath Ethanol concentrations
Blood samples for Ethanol concentrations will be taken - 30 minutes, - 15 and - 5 minutes Pre-Dose, then 15, 30 and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, and 10 hours Post-Dose.
Time frame: From - 30 minutes Pre-Dose to 10 hours Post-Dose
Total Ethanol Dose analyzed by a model independent parameter estimate
Blood samples for Ethanol concentrations will be taken - 30 minutes, - 15 and - 5 minutes Pre-Dose, then 15, 30 and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, and 10 hours Post-Dose.
Time frame: From - 30 minutes Pre-Dose to 10 hours Post-Dose
The record gives a start of Sep 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam